HEALTHEQUITY, INC.
No enriched coverage for $HQY in the last 7 days.
No SEC Form 4 filings for $HQY in the last 30 days.
HealthEquity, Inc. (NASDAQ:HQY) has received a consensus "Moderate Buy" rating from fifteen brokerages, with an average 12-month price target of approximately $111.79. The company recently surpassed earnings per share and revenue expectations for its last quarter. Institutional investors hold a significant 99.55% of the stock.
B. Metzler seel. Sohn & Co. AG increased its stake in HealthEquity, Inc. (NASDAQ:HQY) by 23.5% in the fourth quarter, now owning 104,078 shares valued at approximately $9.54 million. HealthEquity reported stronger-than-expected earnings and revenue in its latest quarter, prompting several analyst upgrades and a "Moderate Buy" consensus rating. The company's stock currently trades at $77.75, with a market capitalization of $6.57 billion.
HealthEquity announced the termination of its Chief Technology Officer and the consolidation of technology, product, and strategy leadership under Sunil Rajasekar. This organizational change is expected to influence how efficiently HealthEquity's tech investments, such as its AI-powered HSAnswers tool, translate into margin performance as the company pursues its digital transformation goals. Investors will be watching how this shift impacts cost control and operating leverage while monitoring potential increases in technology and fraud prevention spending.
